In January 2024, the Russian Ministry of Health, together with the expert center of the Federal State Budgetary Institution “SCEEMP”, published an information letter with recommendations for updating documentation for consumers of diuretics containing acetazolamide as an active substance. Acetazolamide is an inhibitor of the carbonic anhydrase enzyme with weak diuretic activity. Acetazolamide preparations are used to eliminate edema syndrome,